ERBB3 and cancer: This TCE format was inspired by our previous work on a trivalent BiTE, targeting HER3,81 which exhibited increased binding to HER3+ cancer cells compared to the corresponding scDb, resulting in increased T cell activation, proliferation, and induction of T cell-mediated killing.